Filings
| Filing | Date | Type | Filed with |
|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
|---|
| Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
|---|
| F. Hoffmann-La Roche Announces Third Quarter Sales 2026 | Oct 22, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA | Sep 28, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026) | Jul 24, 2026 | Interim report | Tokyo Stock Exchange |
|---|
| F. Hoffmann-La Roche Announces Half Year Results 2026 | Jul 23, 2026 | Interim report | Tokyo Stock Exchange |
|---|